Genzyme — Proxy Contest (May 2010)
17 slides from Genzyme's proxy contest presentation, May 20, 2010
Slide 1: Manufacturing Presentation
May 20, 2010 Manufacturing Presentation
Slide 2: Important Information
Important Information On April 26, 2010, Genzyme filed a definitive proxy statement with the SEC in connection with the company’s 2010 annual meeting of shareholders. Genzyme shareholders are strongly advised to read carefully the company's definitive proxy statement and other proxy materials before
Slide 3: Scott Canute: President of Global Manufacturing & Corporate Operations
Scott Canute: President of Global Manufacturing & Corporate Operations Bio Respected leader in the field with more than 25 years of experience Former President of Global Manufacturing Operations at Eli Lilly & Company Degree in chemical engineering from the University of Michigan MBA Harvard Busines
Slide 4: Ron Branning: Senior Vice President of Global Product Quality
Ron Branning: Senior Vice President of Global Product Quality Bio Over 30 years of experience in biopharmaceutical manufacturing quality and regulatory compliance Led quality and compliance functions at Gilead Sciences as Corporate Vice President of Quality and Compliance and Chief Compliance Office
Slide 5: Biopharmaceutical Manufacturing Is Inherently Complex
Biopharmaceutical Manufacturing Is Inherently Complex 8,500 discrete I/O points 22,000 line items to make one vial of Cerezyme >2,000 site procedures Perfusion, microcarrier processes, 40-110 days in duration Allston Landing Facility
Slide 6: Genzyme Manufacturing: 20-Year Record of Success
Genzyme Manufacturing: 20-Year Record of Success Process Validation initiated for Fabrazyme 1999 Process Validation initiated for Cerezyme 1993 Process Validation initiated for Myozyme FDA approves Fabrazyme 2003 FDA approves Cerezyme 1994 2008 was the first time Genzyme had been impacted by a virus
Slide 7: Introduction to Genzyme Manufacturing
Introduction to Genzyme Manufacturing Framingham, MA Bulk Biologics 2007-2011 Geel, Belgium Bulk Biologics 2001-2004-2009 Waterford, Ireland Fill & Finish 2004 - 2011 Allston Landing Boston, MA Bulk Biologics, Fill & Finish 1996 - 2010
Slide 8: Increasing Manufacturing Capacity 4x from '04 to '12
Increasing Manufacturing Capacity 4x from ‘04 to ‘12 Perfusion Bioreactors 32,000L Allston Geel Framingham Facility location: 2011/12E 2009 2004 Cerezyme 4 x 2KL Fabrazyme 2 x 2KL Myozyme 2 x 4KL 20,000L 4x Increase Cerezyme 3 x 2KL Fabrazyme 1 x 2KL 8,000L Myozyme 3 x 4KL Fabrazyme 3 x 2KL Fabrazym
Slide 9: Cerezyme and Fabrazyme Bulk Production
Cerezyme and Fabrazyme Bulk Production Allston Landing Facility Cerezyme & Fabrazyme are currently manufactured in six 2000L bioreactors Framingham Facility Adds four 2000L bioreactors Design initiated Sep ’07 Construction complete Dec ’09 Regulatory approval expected in late 2011
Slide 10: Myozyme Bulk Production
Myozyme Bulk Production Myozyme is currently manufactured in two 4000L bioreactors in Flanders and in three 160L reactors in Framingham A third 4000L bioreactor is expected to be on-line for commercial production in mid-2011 Genzyme Flanders Belgium facility
Slide 11: Fill Finish Production
Fill Finish Production Exit fill/finish operations at Allston Landing facility. Transferred Cerezyme 400U to Waterford Plan to transfer fill of remaining products to Hospira, KS beginning Q3:10 Fill/finish expansion to 4X in Waterford expected mid-2011 Waterford Ireland Isolated Filling Line
Slide 12: 2009: A Timeline of Events
2009: A Timeline of Events 6 / 30 / 10 10 / 1 / 08 1 / 1 / 09 4 / 1 / 09 7 / 1 / 09 10 / 1 / 09 1 / 1 / 10 4 / 1 / 10 4 / 15 / 09 - 6 / 30 / 09 Quality System Assessments conducted Regulatory Agency Inspections EMEA , ANVISA PMDA , FDA 2 / 27 / 09 FDA Warning Letter - Quality System Improvement Team
Slide 13: Genzyme Took Swift Action to Address Manufacturing Challenges at Allston
Genzyme Took Swift Action to Address Manufacturing Challenges at Allston Made Significant Senior Leadership Changes and Strengthened Governance Hired best-in-class senior leadership with fresh perspectives Established the Board Risk Oversight Committee to provide additional oversight of non financia
Slide 14: What Does Operating Under a Consent Decree Mean?
What Does Operating Under a Consent Decree Mean? The FDA has issued at least 20 consent decrees since 2000 List includes established and respected companies such as Wyeth, Schering-Plough, and GlaxoSmithKline Genzyme subject to a $175 million fine, plus* 18.5% profit disgorgement if certain timeline
Slide 15: Genzyme Took Actions Before the Consent Decree
Genzyme Took Actions Before the Consent Decree Genzyme had been working to implement best-in-class standards before the Consent Decree was issued. This should facilitate seamless integration with existing Allston action. Steps We Took
Slide 16: Core Elements in Place to Achieve Success
Core Elements in Place to Achieve Success Most of our manufacturing network is high quality and state-of-the-art Significant upgrades to biologics capacity and infrastructure Exit Allston fill/finish Quality System remediation is well on its way Facilitates transition towards operating under a Conse
Slide 17: Summary
Summary While much progress has been made there is clearly more for us to do Much of the work that remains is in the many “little” things that must be done right each and every day But we know what needs to be done and how to do it Importantly, Scott Canute and Ron Branning have done it before Overa